Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Press Releases

[Geneva, Switzerland – 3 June 2015]
Child-Friendly Formulation of WHO-Recommended Treatment Now Approved by the US FDA for Children Living with HIV
The Paediatric HIV Treatment Initiative* welcomes this important step towards closing the treatment gap for children with HIV
Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration’s (FDA) tentative approval last week of lopinavir/ritonavir (LPV/r) oral pellets developed by the Indian generic company Cipla.

More

[Geneva, Switzerland; Osaka and Tokyo, Japan; London, United Kingdom – 28 May 2015]
DNDi and Four Pharmaceutical Companies Announce ‘Drug Discovery Booster’ Experiment to Accelerate and Expand Discovery of New Drugs for Two Highly Neglected Diseases – Leishmaniasis and Chagas disease
First multi-company engagement in a single project with DNDi to tackle neglected tropical diseases, supported by the Japanese Global Health Innovative Technology Fund
The Drugs for Neglected Diseases initiative (DNDi) and four pharmaceutical firms, Eisai Co Ltd, Shionogi & Co Ltd, Takeda Pharmaceutical Ltd, and AstraZeneca plc have announced the start of a ground-breaking initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease. The ‘Neglected Tropical Diseases Drug Discovery Booster’ consortium, through a carefully engineered modus operandi, will circumvent early stage commercial barriers between the four pharmaceutical participants, allowing DNDi, for the first time, to search millions of unique compounds simultaneously, in the hunt for new treatment leads for leishmaniasis and Chagas disease.

More

[Geneva, Switzerland, 11 May 2015]
MSF and DNDi Join Call for a Biomedical Research and Development Fund and Mechanism to Meet Pressing Global Health Needs
A group of renowned global health experts*, including from Médecins Sans Frontières (MSF) and the Drugs for Neglected Diseases initiative (DNDi), are calling for the creation of a global health research and development (R&D) fund and mechanism to address deadly gaps in innovation for emerging infectious diseases such as Ebola, anti-microbial resistance, and a host of other diseases that have been neglected by the pharmaceutical market. The call comes at a time when these and other public health challenges are high on political agendas in the lead up to World Health Assembly next week and the G7 Summit in June.

More

[Bogotá, Colombia – April 23, 2015]
Ministry of Health and partners disclose recommendations to overcome barriers to access to diagnosis and treatment for Chagas Disease in Colombia
At an international seminar that gathered international and Colombian experts in Bogotá, capital, representatives of the General System of Social Security in Health, knowledge management, civil society and international cooperation agreed upon necessary measures to rebuild and reinforce proposals to guarantee the right to health on affected areas, including a model project for the treatment of Chagas disease, both at regional and national levels.
[Español] [Português]

More

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License